NATIONAL ACADEMY OF MEDICINE *AND* NATIONAL ACADEMY OF SCIENCES

THE ROYAL SOCIETY

Heritable Human Genome Editing: Rare Disease Week Discussion

February 26, 2021 at 9:00am EST / 2:00pm GMT / 3:00pm CET / 10:00 pm CST

AGENDA

9:00 EST	WELCOME – Sharon Terry, Genetic Alliance
9:10 EST	OPENING PRESENTATION – Kay Davies, University of Oxford and Richard Lifton, Rockefeller University (*Commission Co-chairs*)
9:40 EST	PANEL DISCUSSION
	Moderator: Sharon Terry, Genetic Alliance
	Panelists: Kay Davies, University of Oxford, Richard Lifton, Rockefeller University, Andrew Greenfield, MRC Harwell Institute, Jeffrey Kahn, Johns Hopkins University, and Anna Wedell, Karolinska Institute
10:30 EST	ADJOURN

Participants are encouraged to post questions in the comment box on the event website.

ABOUT THIS EVENT

Heritable human genome editing has been proposed as a means of helping parents with a known risk of passing on a genetic disease to avoid that risk. But can the technology be used safely and if so, in what circumstances should it be considered for any initial use?

Join moderator Sharon Terry, Genetic Alliance, and members of the International Commission on the Clinical Use of Human Germline Genome Editing for a 90 minute online discussion of the implications of this technology for genetic disease and disability communities

Heritable human genome editing—making changes to the genetic material of eggs, sperm, or any cells that lead to their development, including the cells of early embryos—raises scientific and medical considerations, as well as ethical, moral, and societal issues. Reflecting over a year's effort by a Commission of 18 members from 10 countries, the report Heritable Human Genome Editing assesses potential benefits, harms, and uncertainties associated with heritable genome editing technologies and defines a translational pathway from rigorous preclinical research to initial clinical uses, should a country decide to permit such uses.